Dana-Farber Cancer Institute President and CEO Dr. Laurie Glimcher will step down Oct. 1.
Dr. Benjamin Ebert, chair of the medical oncology department, will succeed Glimcher as president and CEO, according to a Tuesday news release.
Related: Dana-Farber, Beth Israel Deaconess to partner on new cancer hospital
Ebert joined Dana-Farber in October 2017, and is a professor at Harvard Medical School, a Howard Hughes Medical Institute investigator and a member of the Broad Institute of MIT and Harvard, in addition to leading a cancer research laboratory, according to the news release.
Tuesday's announcement comes less than a year after Dana-Farber was accused of data manipulation in its research, leading the institute to retract or correct dozens of papers. The accusations, brought by British blogger and molecular biologist Sholto David, called into question some work co-authored by Glimcher and Chief Operating Officer William Hahn and gave a black eye to Dana-Farber's once-stellar reputation.
A spokesperson said Tuesday the leadership change is not related to the research scandal.
Glimcher stepped into her role in October 2016 as the organization's first woman leader. She will become president emerita and continue to pursue research and mentorship opportunities at Dana-Farber, according to the news release.
Under Glimcher's leadership, Boston-based Dana-Farber grew from four to seven regional locations.
Glimcher helped expand Dana-Farber's Cancer Care Equity Program, run a multiyear fundraising campaign and broker a partnership with Beth Israel Deaconess Medical Center in Boston to create a freestanding inpatient cancer hospital in the area. The partnership, announced about a year ago, will eventually sever Dana-Farber's nearly 30-year relationship with Brigham and Women’s Hospital for inpatient and surgical care.
